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Protein-coding genetic variants that strongly affect disease risk can yield relevant clues to disease pathogenesis. Here
we report exome-sequencing analyses of 20,791 individuals with type 2 diabetes (T2D) and 24,440 non-diabetic control
participants from 5 ancestries. We identify gene-level associations of rare variants (with minor allele frequencies of
less than 0.5%) in 4 genes at exome-wide significance, including a series of more than 30 SLC30A8 alleles that conveys
protection against T2D, and in 12 gene sets, including those corresponding to T2D drug targets (P = 6.1 × 10−3) and
candidate genes from knockout mice (P = 5.2 × 10−3). Within our study, the strongest T2D gene-level signals for rare
variants explain at most 25% of the heritability of the strongest common single-variant signals, and the gene-level effect
sizes of the rare variants that we observed in established T2D drug targets will require 75,000–185,000 sequenced cases
to achieve exome-wide significance. We propose a method to interpret these modest rare-variant associations and to
incorporate these associations into future target or gene prioritization efforts.


Human genetics offers a powerful approach for better understanding
and treating disease by identifying molecular alterations that are causally associated with physiological traits1. Common-variant array-based
genome-wide association studies (GWAS) have associated thousands of
genomic loci with hundreds of human traits2, and further analyses indicate that heritability of most complex traits is attributable to modesteffect common regulatory variants3. However, non-coding GWAS associations are challenging to assign to causal variants or genes4.
Protein-coding variants with strong effects on protein function or
disease can offer molecular ‘probes’ into the pathological relevance of
a gene5 and potentially establish a direct causal link6 between gene
gain- or loss-of-function and disease risk7—especially when there
is evidence of multiple independent variant associations (an ‘allelic
series’) within a gene8. Several lines of evidence9 predict that strongeffect variants (allelic odds ratios > 2) will usually be rare (minor allele
frequency (MAF) < 0.5%) and, in many cases, difficult to accurately
study through current array-based GWAS and imputation strategies5.
Whole-genome or whole-exome sequencing, by contrast, allows interrogation of the full spectrum of genetic variation.
Previous exome-sequencing studies have identified relatively few
exome-wide significant rare-variant associations for complex diseases
such as T2D10. This paucity of findings is in part due to the limited
sample sizes of previous studies, the largest of which included less than
10,000 disease cases and fall short of the sample sizes that analytic9
and simulation-based calculations11 predict are needed to identify
rare disease-associated variants under plausible disease models. To
increase rare coding variant analysis power, we collected and analysed
exome-sequencing data from 20,791 T2D cases and 24,440 controls—
one of the largest analyses of exome-sequenced cases for T2D, specifically, and for any disease, more generally.

Genetic discovery from association analysis

Study participants (Supplementary Table 1) were drawn from five
self-reported ancestries: (Hispanic/Latino (effective size (neff ) = 14,442;
33.8%), European (n eff = 10,517; 24.6%), African-American
(neff = 5,959; 13.9%), East-Asian (neff = 6,010; 14.1%) and SouthAsian (neff = 5,833; 13.6%)) and yielded equivalent statistical power
to detect associations as a balanced study of around 42,800 individuals
or a population-based study (assuming T2D prevalence of 8% and no

ascertainment bias) of around 152,000 individuals. Power was
improved compared to the previous largest T2D exome-sequencing
study10 of 6,504 cases and 6,436 controls, increasing, for example,
from 5% to 90% for a variant with MAF = 0.2% and odds ratio = 2.5
(Extended Data Fig. 1).
Exome sequencing to 40x mean depth, variant calling and quality
control (Extended Data Fig. 2, Supplementary Methods, Supplementary
Figs. 1–3 and Supplementary Table 2) produced a dataset with 6.33 million variants: 2.3% common (MAF > 5%), 4.2% low-frequency
(0.5% < MAF < 5%) and 93.5% rare (MAF < 0.5%) (Supplementary
Table 3). These include 2.26 million nonsynonymous variants and
871,000 insertions and deletions (indels), more than twice the number
of variants that were analysed in a previous T2D exome-sequencing
study10.
We first tested each variant, regardless of allele frequency, for T2D
association (‘single-variant’ test; Methods and Extended Data Figs. 3,
4). Fifteen variants (in seven loci) exceeded exome-wide significance
(P < 4.3 × 10−7 for coding variants12, P < 5 × 10−8 for synonymous
or non-coding variants), including ten nonsynonymous variants
(Fig. 1a and Extended Data Table 1). These 15 associations are a substantial increase over the single association that was reported in a previous T2D-exome sequencing study10 and illustrate again the value
of multi-ancestry association analyses13—as only 9 out of 15 variants
achieved P < 0.05 in European samples. However, only two variants
were not previously reported by GWAS: a variant in SFI1 (rs145181683,
Arg724Trp; Supplementary Fig. 4) that failed to replicate in an independent cohort (n = 4,522, P = 0.90; Methods) and a low-frequency
(in Hispanic/Latino individuals; MAF = 0.89%) moderate-effect (odds
ratio = 2.17, 95% confidence interval = 1.63–2.89) MC4R variant
(rs79783591, Ile269Asn) that has previously been shown to decrease
MC4R activity and to be associated with obesity and T2D in smaller
studies14. Conditioning on body-mass index reduced but did not eliminate the MC4R Ile269Asn T2D association (P = 1.0 × 10−5).
Because single-variant analyses have limited power to detect
rare-variant associations9, we next performed association tests for
aggregations of variants within genes. Because numerous variant
aggregation approaches (that is, ‘masks’) and gene-level tests are available, we developed a method (Methods, Extended Data Figs. 5, 6 and
Supplementary Figs. 5, 6) to consolidate information across 14 analyses
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into four results per gene: burden9 and SKAT15 analyses, each of which
were either summarized as the ‘minimum P value’ across masks or
‘weighted’ to estimate the effect of gene haploinsufficiency. We used
an exome-wide gene-level significance threshold of P = 6.57 × 10−7
(Methods).
Using this strategy, gene-level associations were exome-wide significant for MC4R, SLC30A8 and PAM (Fig. 1b, Extended Data Table 2 and
Supplementary Table 4), with variants from multiple ancestries contributing to each signal (Methods). All three genes lie within reported T2D
GWAS loci and contain previously identified coding variant signals: the
common variant Arg325Trp and 12 rare protective protein-truncating
variants (PTVs) for SLC30A87,16, the low-frequency variants Asp563Gly
and Ser539Trp for PAM10,17 and the low-frequency variant Ile269Asn
for MC4R.
The associations in MC4R (combined MAF = 0.79%, minimum
P = 2.7 × 10−10, odds ratio = 2.07, 95% confidence interval = 1.65–
2.59) and PAM (combined MAF = 4.9%, weighted P = 2.2 × 10−9,
odds ratio = 1.44, 95% confidence interval = 1.28–1.62) result largely
from effects of the previously identified coding variants in these genes,
although the MC4R signal remained nominally significant after removing
Ile269Asn (P = 8.6 × 10−3; Supplementary Fig. 7) and the PAM signal
remained nominally significant (P < 0.05) after removing the 35 strongest individually associated PAM variants (Supplementary Fig. 8). As
illustrated by a recent study that identified a novel T2D risk mechanism
through cellular characterization of PAM Asp563Gly and Ser539Trp18,
variants identified in our study (uniquely from sequencing)6 could yield
further insights into the T2D risk mechanism mediated by PAM.
In contrast to MC4R and PAM, the SLC30A8 signal (103 variants,
combined MAF = 1.4%, weighted P = 1.3 × 10−8, odds ratio = 0.40,
95% confidence interval = 0.28–0.55) was not primarily driven by an
individual variant (Arg325Trp (MAF > 1%) was not included in the
gene-level analysis). The association was instead driven by 90 missense
variants (weighted P = 3.9 × 10−7) and remained nominally significant (P < 0.05) even when we removed the 32 strongest individually associated SLC30A8 variants (Fig. 1c and Supplementary Fig. 9).
Although SLC30A8 was first implicated in T2D over a decade ago16, the
disease-associated molecular mechanism(s) through which SLC30A8
acts remain poorly understood19—in part because the common riskincreasing allele Arg325Trp and the rare risk-decreasing PTVs were
both initially thought to decrease protein activity7,19. The protective
allelic series from our analysis argues that decreased T2D risk is the
typical effect of SLC30A8 missense variation—that is, it is not unique
to haploinsufficiency—and provides many additional alleles that can
be characterized to gain mechanistic insights.
To evaluate association evidence for genes other than MC4R, PAM
and SLC30A8, we assessed the 50 most-significant gene-level associations from our study in two independent exome-sequencing datasets:
12,467 European or African-American individuals (3,062 T2D cases)
from the CHARGE discovery sequencing project20 (Supplementary
Table 5; 50 genes available) and 49,199 European individuals
(12,973 T2D cases) from the Geisinger Health System (Supplementary
Table 6; 44 genes available). In a meta-analysis of the three studies
(Methods and Supplementary Table 7), MC4R (P = 6.9 × 10−14), PAM
(P = 3.0 × 10−9) and SLC30A8 (P = 3.3 × 10−8) each became more
significant. In addition, one gene, UBE2NL (P = 5.6 × 10−7)—which
has few prior links to T2D or other complex traits—newly achieved
exome-wide significance (http://www.type2diabetesgenetics.org/).
All aspects of this association passed quality control (Methods and
Supplementary Table 8), although further replication will be important
to establish UBE2NL as a novel T2D-relevant gene.
More broadly, we observed an excess of directionally consistent
associations (both odds ratio > 1 or both odds ratio < 1) between
the original and replication analyses (31 out of 46 in CHARGE, onesided binomial P = 0.013; 23 out of 40 in the Geisinger Health System,
P = 0.21; overall P = 0.011; Supplementary Table 7), suggesting that
several more of our top gene-level signals will reach exome-wide significance in future studies.
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Further insights from gene-level analyses

Even if a gene-level association does not achieve exome-wide significance, it might still be of use to prioritize a gene as relevant to T2D8 or
predict whether loss or gain of protein function increases disease risk7. To
investigate potential insights that could be obtained by sub-exome-wide
significant gene-level associations, we analysed 16 gene sets that
were connected to T2D based on a variety of sources of evidence (for
example, genes that contained diabetes-associated Mendelian variants,
T2D drug targets21 or genes that have been implicated in diabetesrelated phenotypes in mouse models22; Methods and Supplementary
Table 9).
First, for each gene set, we investigated whether the genes within
the set had more significant gene-level associations than expected by
chance (Methods). In total, 12 out of 16 gene sets achieved P < 0.05
set-level associations (Fig. 2a–e and Supplementary Fig. 10), including
T2D drug targets (P = 2.1 × 10−3), genes previously reported in mouse
models of non-insulin-dependent diabetes (NIDD; P = 5.2 × 10−3)
or impaired glucose tolerance (P = 7.2 × 10−6) and genes that contained common likely causal coding-variant T2D associations6
(P = 8.8 × 10−3 after conditioning on the common variants nearby
these genes). Additionally, as previously described10, we observed a
significant set-level association (P = 1.2 × 10−3) for genes implicated
in maturity onset diabetes of the young (MODY; Fig. 2a, Supplementary
Table 10), with nominal associations in four genes including PDX1
(weighted P = 1.7 × 10−4, odds ratio = 3.45, 95% confidence interval = 1.78–6.71, 65 variants). Rare variants in genes associated with
MODY also demonstrated aggregate association with lower body-mass
index (minimum P = 5.7 × 10−3) and lower fasting insulin (minimum P = 0.028), consistent with the known predominant variant
risk mechanism of reduced insulin secretion in MODY23. Most gene
set signals were driven by multiple genes in the set (Supplementary
Table 11) and—compared with previous studies focused on PTVs24—
consisted of substantial contributions from missense variants. Indeed,
set-level P values from PTVs alone were >0.05 for almost all gene sets
(Supplementary Fig. 11).
Collectively, these results suggest that association strength at the gene
level can be used as a potential metric to prioritize candidate genes
relevant to T2D. For example, the set of 40 genes within T2D GWAS
loci with gene-level P < 0.05 had a significant excess of protein–protein
interactions among them (Methods and Supplementary Table 12),
suggesting that this set may be enriched for ‘effector genes’ that mediate T2D GWAS associations6. Fully evaluating the relevance to T2D
of these and other candidate genes will require further experimental
work4.
In addition to prioritizing genes that are potentially relevant to T2D,
we assessed whether gene-level analysis could help to predict whether
gene inactivation increases or decreases T2D risk, as this is of high
interest for the development of therapeutics8. We compared the odds
ratios that were estimated from a gene-level weighted burden analysis to directional relationships that have been previously reported
(Methods). Seven out of eight T2D drug targets showed concordance
between genetic and therapeutic directions of effect (three out of four
inhibitor targets had an odds ratio < 1, four out of four agonist targets
had an odds ratio > 1; one-sided binomial P = 0.035; Fig. 2f). The only
exception was KCNJ11 (odds ratio = 1.59, inhibited by sulfonylureas),
for which the gene-level signal was driven by a known25 activating missense mutation (His172Arg); an analysis without this variant predicted
the correct (odds ratio < 1) directional relationship. This finding is
consistent with the known reciprocal roles of KCNJ11 in both diabetes
and persistent hyperinsulinaemic hypoglycaemia of infancy.
Concordances between gene-level estimates of odds ratios and
knockout effects in mice were more equivocal (for example, 7 out of 11
diabetes-associated genes had an odds ratio > 1, binomial P = 0.27; 137
out of 240 genes associated with increased circulating glucose had an
odds ratio > 1, P = 0.016; Supplementary Fig. 12). The lower concordances for these gene sets, despite a trend towards lower-than-expected
gene-level P values within them (Supplementary Fig. 10), highlight the
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Fig. 1 | Exome-wide association analysis. a, Single-variant
associations were calculated using the two-sided EMMAX test. Red
line, P = 4.3 × 10−7. b, Gene-level P values, corrected for four analyses
performed using the two-sided minimum P-value test. The mostsignificant genes are labelled. Red line, P = 6.5 × 10−7. c, SLC30A8
gene-level P values (left y axis, black line), calculated using a two-sided

burden test after removing variants (in order of increasing single-variant
P value) from the 1/5 1% mask (the strongest signal for SLC30A8). Dashed
line, P = 0.05. Right y axis (blue line), estimated effect size (log10(odds
ratio)). Blue shading, 95% confidence interval. Dotted line, effect size = 0.
Single-variant n = 45,231 individuals. Gene-level n = 43,074 unrelated
individuals.

known limitations of animal models26, which can be highly dependent
on model conditions27, to predict human physiology. Candidate genes
with significant but directionally unexpected gene-level associations
may provide valuable insights into seemingly promising preclinical
results: for example, the protective gene-level signal for ATM in our
analysis (burden test of PTVs odds ratio = 0.50, P = 0.003) contradicts previous expectations—based on insulin resistance and impaired
glucose tolerance in Atm knockout mice28—that ATM loss-of-function
should increase T2D risk. Evidence is even less favourable that ATM
haploinsufficiency strongly increases T2D risk, rejecting an odds
ratio > 2 at P = 1.3 × 10−8. These observations could be relevant in
the ongoing study of whether ATM has a role in metformin response29
or whether ATM activators are considered able to treat cardiovascular
disease30.

To compare discoveries that were possible from sequencing and
array-based studies, we collected genome-wide array data within the
same individuals that we sequenced (available for 34,529 (76.3%)
individuals; 18,233 cases), imputed variants using best-practice reference panels32,33 and conducted a single-variant association analysis
(‘imputed GWAS’; Methods and Supplementary Table 13). Out of 10
exome-wide significant nonsynonymous single-variant associations
from the sequence analysis, 8 were detected in the imputed GWAS
analysis (PAX4 Arg192His and MC4R Ile269Asn were not imputable),
together with genome-wide significant non-coding variant associations in 14 additional loci (Fig. 3a and Supplementary Table 14). All
10 variants with significant single-variant sequence associations were
also present on the Illumina Exome Array6. These results demonstrate
the limited power of sequencing to detect single-variant associations
beyond array-based genotyping and imputation, even before considering the much larger sample sizes enabled by the substantially lower
cost of array-based genotyping.
We next compared the contributions to T2D heritability of the
strongest (common) single-variant associations from the imputed
GWAS to those of the strongest (mostly rare-variant) gene-level associations from the sequencing analysis (Methods). The three exomewide significant gene-level signals explain an estimated 0.11% (MC4R),
0.092% (PAM) and 0.072% (SLC30A8) of T2D genetic variance, only
10–20% of the variance explained by the three strongest independent
common-variant associations in the imputed GWAS (TCF7L2, 0.89%;
KCNQ1, 0.81%; CDC123, 0.35%; Fig. 3b). More broadly, fitting a previous exponential model of heritability34 to our data (Methods) estimated
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Despite early arguments that rare-variant studies would considerably advance our understanding of complex diseases5, most genetic
discoveries continue to be provided by studies of common variants,
which can be studied in much larger sample sizes through array-based
genotyping and imputation31. Previous quantitative analyses have
similarly emphasized the main contribution of common variants to
T2D heritability6,10, but they have lacked the sequencing data that are
needed to fully evaluate the value added by rare variants (that is, direct
sequencing in addition to array-based genotyping and imputation) to
discover disease-associated loci, explain disease heritability and elucidate allelic series.
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Signals ranked by liability variance explained. c, Gene rank percentiles
from exome-sequencing gene-level analysis (x axis) and a previous multiancestry T2D GWAS13 (y axis). Genes are from the mouse NIDD gene set
(Fig. 2c).

that the top 100 gene-level signals associated with T2D explained only
1.96% of genetic variance within our study. These results argue against
a large contribution to T2D heritability from even the strongest genelevel signals, even after accounting for potential sources of downward
bias in our calculations (see Methods).
We finally assessed whether an array-based GWAS could have
detected the many potential allelic series that we observed from direct
sequencing. Among the variants that contributed to the exome-wide
significant gene-level associations in SLC30A8, MC4R and PAM, we
estimate that 95.3% of variants are not imputable (r2 > 0.4; Methods) in
the 1000 Genomes multi-ancestry reference panel32, 74.6% of those in
Europeans are not imputable in the larger European-focused Haplotype
Reference Consortium panel10 and 90.2% (79.7% of European variants)
are absent from the Illumina Exome Array. Additionally, gene set associations (using gene ‘scores’; see Methods) from the imputed GWAS
showed suggestive associations (four gene sets achieved P < 0.05, nine
achieved P < 0.1; Supplementary Fig. 13) but were weaker than gene
set associations from the sequencing analysis. Some of these gene set
associations are detectable in larger array-based studies: analysis of a
110,000-sample multi-ancestry GWAS13 produced P < 0.05 for 12 out
of 16 gene sets that we studied (Supplementary Fig. 14); however, the
genes (and corresponding variants) that are responsible for the arraybased gene set associations were mostly different from those responsible for the sequence-based associations, as the two methods often
produced uncorrelated rank orderings of genes within gene sets (for
example, r = −0.11, P = 0.57 for the mouse NIDD gene set; Fig. 3c).
Collectively, these results demonstrate the complementarity of
array-based GWAS and exome sequencing, with the former favouring
locus discovery and the latter enabling full enumeration of potentially
informative alleles.

influenced by imperfect calibration of association test statistics. If this
false-positive rate can be quantified using independent ‘truth’ data36,
however, then a modest association signal could help to justify further
experimentation on a gene based on the likelihood that it is a true
association, the cost of the experiment and the benefit of success37
(Fig. 4b).
We developed and evaluated a method to quantify the false-positive
association rate for nonsynonymous variants in our dataset by using
independent data, modelling assumptions and prior data to map
single-variant P values to estimated posterior probabilities of true,
causal associations (PPAs) (Methods and Extended Data Fig. 7).
Model parameters in the middle of the range that we explored
(Methods and Extended Data Fig. 8) predict that 1.5% (95% confidence
interval = 0.74–2.2%) of nonsynonymous variants that achieve P < 0.05
in our study are truly, causally associated with T2D, increasing to 3.6%
(95% confidence interval = 1.4–5.9%) for P < 0.005 and 9.7% (95%
confidence interval = 3.9–15.0%) for P < 5 × 10−4 (Supplementary
Fig. 16). In this model, 541 (95% confidence interval = 270–810) of the
36,604 nonsynonymous variants with P < 0.05 in our study represent
true, causal associations.
We next applied this method to variants within a curated set of
94 T2D GWAS loci (Methods), which might be expected to show further enrichment of true associations. Our model predicted that nonsynonymous variants within these loci had even higher PPAs: 2.0%
(95% confidence interval = 0.048–4.0%) of such variants overall, 8.1%
(3.6–12.4%) with P < 0.05 in our study and 17.2% (7.7–24.1%) with
P < 0.005 were estimated to represent true, causal T2D associations. Of
particular note are variants in these loci that not only achieve nominal
significance (P < 0.05) in our analysis but also have moderate-to-large
estimated effects on T2D risk (Supplementary Tables 15, 16), as we
predict that a substantial number of these variants (for example, 76
(95% confidence interval = 29–117) out of 746 with estimated odds
ratio > 2 and 50 (95% confidence interval = 19–77) out of 503 with
estimated odds ratio > 3) show true, causal associations.
Outside of GWAS loci, many genes are suspected to be involved in
T2D because of prior evidence from non-genetic sources (for example, animal studies22 or because of implication in related disorders23).
To evaluate variants in such genes, we extended our PPA estimation approach to incorporate gene prior probabilities (or ‘priors’)38
(Methods and Extended Data Fig. 7d) and applied it to two sets of
genes.
First, using a prior of 100% for genes associated with MODY—thus
assuming that all genes implicated in MODY are relevant to T2D—
our model predicts 24 variants (combined MAF = 1.1%) to have
PPA ≥ 40% (Supplementary Table 17). Nine have estimated odds
ratio > 3 in our study; as none of these were previously reported to
be pathogenic MODY variants, they are therefore novel rare-variant

Inferences from nominally significant associations

The T2D drug targets analysed here illustrate the opportunities and
challenges of using current exome-sequencing datasets in translational research. Rare-variant gene-level associations are significant
across these targets as a set (Fig. 2b) and predict the correct T2D
directional relationship for all but one gene (Fig. 2f). However, to
detect—at exome-wide significance—the effect sizes estimated from
our study with 80% power would require 75,000–185,000 sequenced
cases (150,000–370,000 exomes in a balanced study, or 600,000–
1,275,000 exomes from a population with a prevalence of T2D of 8%;
Fig. 4a and Methods).
As a consequence, many of the modest associations (for example,
P = 0.05) in current samples may point to clinically or therapeutically
relevant variants or genes (Supplementary Fig. 15). The false-positive
rate for these associations is expected to be greater than the false-positive
rate for exome-wide significant associations 35 and be further
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Predicted power to detect known T2D drug targets
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Fig. 4 | Decision support from exome-sequencing data. a, Estimated
power, as a function of future sample size (x axis), to detect T2D gene-level
associations (two-sided test at P = 6.25 × 10−7) with aggregate frequency
and odds ratios equal to those estimated from our analysis of 8 T2D drug
targets (Fig. 2f). b, A proposed workflow for using exome-sequencing
data in gene characterization. Depending on the prior belief in the disease

relevance of a gene, the cost of experimental characterization and the
benefit of gene validation, a decision to conduct the experiment could
be informed by the posterior probability of the disease relevance of the
gene, as estimated from exome-sequencing association statistics (available
through http://www.type2diabetesgenetics.org/).

candidates for use in the prediction of T2D risk. On the other hand,
these results show that, once false-positive rates are empirically estimated rather than assumed, nominally significant variants (P = 0.05)
in genes associated with MODY are still, in absolute terms, more likely
to be false-positive rather than true associations39.
Second, as an example of a gene prior that was derived objectively
(rather than subjectively), we used a mixture model approach40 to
estimate the proportion of non-null associations across the mouse
NIDD gene set (Methods), leading to a prior of approximately 23%
for genes of which knockout causes NIDD in mice. Our model with
this prior (Supplementary Table 18) predicts nonsynonymous variants that achieved P < 0.05 to have PPAs of 9.9% (PPAs of 24.6%
for P < 0.005). In particular, we predict several nonsynonymous
variants in MADD and NOS3 to have PPA ≥ 14% (Supplementary
Table 19), suggesting links between variation in these genes and T2D
based on combined evidence from human genetic studies and mouse
models41,42.
Although these PPA calculations have limitations (Methods), they
present a framework to use suggestive genetic signals to support cost–
benefit estimates of ‘go/no-go’ decisions43 in the language of decision
theory37 (Fig. 4b). To enable this strategy, we have made our exomesequencing association results publically available through the AMP
T2D Knowledge Portal (http://www.type2diabetesgenetics.org/), which
supports queries of precomputed associations and further enables
dynamic recomputations of associations with custom covariates and
sample- and/or variant-filtering criteria.

For personalized medicine, exome sequencing may produce some rare
variants with sufficient effect sizes (Supplementary Tables 12, 17) to
provide viable contributions to the prediction of genetic risk; however,
these are sufficiently rare to be best viewed as complements to rather
than replacements for GWAS-derived polygenic risk scores45. Wholegenome sequencing might soon become sufficiently cost-effective to
subsume both array-based GWAS and exome sequencing; even now,
it is essential to expand imputation reference panels to power higherresolution GWAS across all major ethnicities.
Our results suggest that, for now, maximizing the utility of exome
sequencing will require drawing insights from associations that do not
(yet) reach exome-wide significance. To help to interpret these suggestive associations, we present a principled and empirically calibrated
Bayesian approach (Fig. 4, Extended Data Fig. 7 and Supplementary
Table 18) to estimate the association probability for any variant in our
dataset, highlighting its use to interpret variants in known disease genes
and prioritize genes from animal model studies for further investigation. Results and customized analyses from our study can be accessed
through a public web portal (http://www.type2diabetesgenetics.org/),
advancing the use of exome-sequencing data across many branches of
biomedical research.

Discussion

Our results provide a nuanced description of rare variation and its association with T2D, which might also apply to other complex diseases.
Rare-variant gene-level signals are likely to be distributed across numerous genes; however, the vast majority of signals individually explain
vanishingly small amounts of T2D heritability: more than one million
samples may be required for rare-variant signals in validated therapeutic targets to become significant exome-wide. Even among the four
genes that reached exome-wide significance in our analysis, two (MC4R
and PAM) do not include unusually strong rare-variant associations
but rather typically modest rare-variant associations that are boosted
from nominal to exome-wide significance by low-frequency variants.
Thus, for biological discovery in many complex traits, such as T2D,
exome sequencing and array-based GWAS seem complementary: locus
discovery and fine mapping are achieved most efficiently using larger
array-based GWAS, whereas rare coding variant allelic series—that
could aid experimental gene characterization44 or provide confidence in
disease-gene identification—are best discoverable through sequencing.
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Methods

A full description of the methods used in this study is available as Supplementary
Methods.
Data reporting. The experiments were not randomized and the investigators were
not blinded to allocation during experiments and outcome assessment.
Sample selection. We drew samples for exome sequencing from six consortia, most
of which consisted of multiple studies and are described fully in Supplementary
Table 1. T2D case status was determined according to study-specific criteria
described in full in in Supplementary Table 1 and the Supplementary Methods.
All individuals provided informed consent and all samples were approved for use
by their institution’s institutional review board or ethics committee, as previously
reported10,46–48. Samples that were newly sequenced at The Broad Institute as
part of T2D-GENES, SIGMA and ProDiGY are covered under Partners Human
Research Committee protocol 2017P000445/PHS ‘Diabetes Genetics and Related
Traits’.
Data generation. The details of data generation, variant calling, quality control and
variant annotation are described in full in the Supplementary Methods. In brief,
for each consortium, sequencing data were aggregated (if previously available) or
newly generated (if not) and then processed through a standard variant calling
pipeline. We then measured samples and variants according to several metrics
indicative of sequencing quality, excluding those that were outliers relative to the
global distribution (Supplementary Fig. 1, Supplementary Table 2). These exclusions produced a ‘clean’ dataset of 49,484 samples and 7.02 million variants.
Following initial sample and variant quality control, we performed additional
rounds of sample exclusion from association analysis (Extended Data Fig. 2). We
also excluded the 3,510 childhood diabetes cases from the SEARCH and TODAY
studies based on an analysis that suggested their lack of matched controls would
induce artefacts in gene-level association analyses (Supplementary Fig. 17). These
exclusions produced an ‘analysis’ dataset of 45,231 individuals and 6.33 million variants. A power analysis of this dataset is presented in the Supplementary Methods.
After these three rounds of sample exclusions, we estimated—within each ancestry—pairwise identity-by-descent values, genetic relatedness matrices and principal
components for use in downstream association analyses. We used the identity-by-descent values to generate lists of unrelated individuals within each ancestry,
excluding 2,157 individuals to produce an ‘unrelated analysis’ set of 43,090 individuals (19,828 cases and 23,262 controls) and 6.29 million non-monomorphic
variants. We used this set of individuals and variants for single-variant and genelevel tests (described below) that required an unrelated set of individuals.
We annotated variants with the ENSEMBL Variant Effect Predictor49 (VEP,
version 87). We produced both transcript-level annotations for each variant as
well as a ‘best guess’ gene-level annotation using the –flag-pick-allele option (with
ranked criteria described in the Supplementary Methods). We used the VEP LofTee
(https://github.com/konradjk/loftee) and dbNSFP (version 3.2)50 plugins to generate additional bioinformatics predictions of variant deleteriousness; from the
dbNSFP plugin, we took annotations from 15 different bioinformatics algorithms
(listed in Extended Data Fig. 5) and then added annotations from the mCAP51
algorithm. As these annotations were not transcript-specific, we assigned them to
all transcripts for the purpose of downstream analysis.
Although we incorporated both transcript-level and gene-level annotations into
gene-level analyses (see below), all single-variant analyses reported in the manuscript or figures are annotated using the ‘best guess’ annotation for each variant.
Single-variant association analysis in sequencing data. To perform single-variant
association analyses, we first stratified samples by cohort of origin and sequencing technology (with some exceptions described in the Supplementary Methods),
yielding 25 distinct sample subgroups (Extended Data Fig. 3). For each subgroup,
we performed additional variant quality control beyond that used for the ‘clean’
dataset, excluding variants according to subgroup-specific criteria described in
Extended Data Fig. 3; in general, these criteria were strict—particularly for multiallelic variants and X-chromosome variants. We verified that these filters led to a
well-calibrated final analysis through inspection of quantile–quantile plots within
and across ancestries (Extended Data Fig. 4).
For each of the 25 sample subgroups, we then conducted two single-variant
association analyses: one of all (including related) samples using the (two-sided)
EMMAX test52 and one of unrelated samples using the (two-sided) Firth logistic
regression test53. Both analyses included covariates for sequencing technology, and
the Firth analysis included covariates for principal components of genetic ancestry
(those among the first 10 that showed P < 0.05 association with T2D).
We then conducted a 25-group fixed-effect inverse-variance weighted
meta-analysis for each of the Firth and EMMAX tests, using METAL54. We used
EMMAX results for association P values and Firth results for effect size estimates.
Additional analysis of rs145181683. To assess whether the rs145181683 variant in
SFI1 (P = 3.2 × 10−8 in the exome-sequencing analysis) represented a true novel
association, we obtained association statistics from 4,522 Latinos55) who did not
overlap with the current study. On the basis of the odds ratio (1.19) estimated in

our analysis and the MAF (12.7%) in the replication sample, the power was 91%
to achieve P < 0.05 under a one-sided association test. The observed evidence
(P = 0.90, odds ratio = 1.00) did not support rs145181683 as a true T2D association. Further investigation of this lack of replication evidence suggested that,
although the association from our sequence analysis is unlikely to be a technical
artefact (genotyping quality was high), it could possibly be a proxy for a different
(Native American-specific) non-coding causal variant (full details are available in
the Supplementary Methods). Further fine-mapping and replication efforts will
be necessary to test this hypothesis.
Gene-level analysis. For each gene, following previous studies10,56,57, we separately
tested seven different ‘masks’ of variants grouped by similar predicted severity
(defined in Extended Data Fig. 5). For each gene and each mask, we created up to
three groupings of alleles, corresponding to different transcript sets of the gene; for
many genes, two or more of these allele groupings were identical.
Before running gene-level tests, we performed additional quality control on
sample genotypes. For each of the 25 sample subgroups (the same as used for
single-variant analyses), we identified variants that failed subgroup-specific quality control criteria (shown in Extended Data Fig. 5) and set genotypes for these
variants in all individuals in the subgroup as ‘missing’.
We conducted two gene-level association tests: a burden test, which assumes all
analysed variants within a gene are of the same effect, and SKAT15, which allows
variability in variant effect size (and direction); each of these tests is two-sided.
We performed each test across all unrelated individuals with 10 principal components of genetic ancestry, sample subgroup and sequencing technology as covariates. As this ‘mega-analysis’ strategy was different from the meta-analysis strategy
that we used for single-variant analyses, as a quality control exercise we conducted
a single-variant mega-analysis and found that its results showed broad correlation
with those from the original meta-analysis (Supplementary Fig. 18).
We then developed two methods to consolidate the 2 × 7 = 14 P values produced for each gene (described in full in Extended Data Fig. 5, Supplementary
Methods and Supplementary Figs. 5, 6). First, we corrected the smallest P value
for each gene according to the effective number of independent masks tested for
the gene (variable, but on average 3.6), based on the gene-specific correlation of
variants across masks58 (referred to as the minimum P-value test; Supplementary
Fig. 19). Second, we tested all nonsynonymous variants (that is, missense, splice
site and protein-truncating mutations), but weighted each variant according to its
estimated probability of causing gene inactivation9 (referred to as the weighted test,
which essentially assessed the effect of gene haploinsufficiency from combined
analysis of protein-truncating and missense variants; Supplementary Fig. 6). We
verified that these two consolidation methods were well-calibrated (Extended Data
Fig. 6) and broadly consistent yet distinct: across the 10 most significantly associated genes, P values were nominally significant using both methods for 8 genes
but varied by 1–3 orders of magnitude (Extended Data Table 2).
Because each gene mask could in fact represent up to three sets of alleles (owing
to the transcript-specific annotation strategy that we used), for each of the four
analyses multiple P values were possible for some genes. To produce a single genelevel P value for each of the four analyses, we thus collapsed (for each gene) the
set of P values across transcript sets into a single gene-level P value using the
minimum P-value test.
We used a conservative Bonferroni-corrected gene-level exomewide significance threshold of P = 0.05/(2 tests × 2 consolidation methods × 19,020 genes) = 6.57 × 10−7. For each gene referenced in the manuscript,
we report the P value and odds ratio from the analysis that achieved the lowest P
value for the gene.
Gene-level analysis near T2D GWAS signals. In principle, a nearby commonvariant association could lead to over- or underestimation of the strength of a
gene-level association59. To assess whether differential patterns of rare variation
across common-variant haplotypes could significantly affect our gene-level results,
we conducted two analyses (described in the Supplementary Methods) and found
no evidence that confounding from common-variant haplotypes was primarily
responsible for the associations that were observed in our gene-level analyses.
Further exploration of significant gene-level associations. For our exome-wide
significant gene-level associations (MC4R, PAM and SLC30A8), we conducted
additional gene-level analyses to dissect the aggregate signals that were observed.
First, we performed tests by progressively removing alleles in order of lowest singlevariant analysis P value, in order to understand the (minimum) number of alleles
that contributed statistically to the aggregate signal. Second, we performed tests
conditional on each allele in the sequence (that is, calculating separate models with
each individual allele as a covariate), and we then compared the resulting P values to
the full gene-level P value, in order to assess the contribution of each allele individually to the signal. Finally, for MC4R, we conducted an analysis with an added sample
covariate for body-mass index and found that it, as shown previously60,61, reduces
the significance of both the Ile269Asn single-variant signal (P = 1.0 × 10−5) and
the gene-level signal not attributable to Ile269Asn (P = 0.035).

RESEARCH Article
To evaluate which ancestries contributed variants to MC4R, SLC30A8, and PAM,
we calculated the proportion of variants in each signal unique to an ancestry and
also compared the significance and direction of effect of each signal across ancestries. Across the three signals, 68.4% (287 out of 419) of variants in total were
unique to one ancestry (63.9% for MC4R, 67.0% for SLC30A8 and 71.6% for PAM).
Each signal had a direction of effect that was consistent across all five ancestries
and each signal achieved P < 0.05 in at least two ancestries (MC4R in East-Asians
and Hispanics; SLC30A8 in all ancestries other than African-Americans; and PAM
in Europeans, South-Asians and Hispanics).
Analysis of exomes from the Geisinger Health System. We obtained gene-level
association results that were previously computed from an analysis of 49,199 individuals (12,973 T2D cases and 36,226 controls) from the Geisinger Health System
(GHS). Association statistics were available for 44 out of the 50 genes with the
strongest gene-level associations from our study. A power analysis of the GHS
replication analysis is available in the Supplementary Methods.
GHS sequencing data were processed and analysed as previously described24,
and variants were grouped into four (nested) masks (roughly corresponding to the LofTee, 5/5, 1/5 1% and 0/5 1% masks; more details are available in
the Supplementary Methods). For each mask, association results were computed
using two-sided logistic regression under an additive burden model (with phenotype regressed on the number of variants carried by each individual) with age, age2
and sex as covariates. To produce a single GHS P value for each gene, we applied
the minimum P-value procedure across the four mask-level results.
Analysis of exomes from the CHARGE consortium. We collaborated with the
CHARGE consortium to analyse the 50 genes with the strongest gene-level associations from our study in 12,467 individuals (3,062 T2D cases and 9,405 controls)
from their previously described study62,63. A power analysis of the CHARGE replication analysis is available in the Supplementary Methods.
Variants in the CHARGE exomes were annotated and grouped into seven masks
using the same procedure as for the original exome-sequencing analysis. Burden
and SKAT association tests were then performed in the Analysis Commons64
using a two-sided logistic mixed model65 assuming an additive genetic model and
adjusted for age, sex, study, race and kinship. To produce a single CHARGE P value
for each gene, we applied the minimum P-value procedure across the seven masklevel results, as for the GHS analysis.
Meta-analysis with CHARGE and GHS. We conducted a meta-analysis among
our original burden analysis and those of CHARGE and GHS. For each gene,
we selected the mask that achieved the lowest P value in our original analysis
and conducted a two-sided sample-size weighted meta-analysis with the results
from CHARGE and GHS for the same mask (or an analogous mask as defined in
the Supplementary Methods).
Investigation of the UBE2NL association. We investigated the novel association that was found in the gene-level meta-analysis (UBE2NL, meta-analysis
P = 5.6 × 10−7) in more detail. The UBE2NL burden signal was due to five PTVs
in the original analysis (observed in 29 cases and 1 control; all of which had high
(>45×) sequencing coverage; Supplementary Table 8) and was replicated at
P = 0.02 in CHARGE; UBE2NL results were not available in GHS. As UBE2NL
lies on the X chromosome, we conducted a sex-stratified analysis of the original
samples and observed independent associations in both men (P = 5.7 × 10−4) and
women (P = 1.6 × 10−3). UBE2NL does not lie near any known GWAS associations (http://www.type2diabetesgenetics.org/) and has few available references66–68,
suggesting that it may be a novel T2D-relevant gene, although further replication
will be important to establish its association.
Evaluation of directional consistency between exome-sequencing, CHARGE and
GHS analyses. We examined the concordance of direction of effect size estimates
(that is, both odds ratios of >1 or <1) between burden tests from our original
exome-sequencing analysis and those from CHARGE and GHS. For the 46 genes
advanced for replication with burden P < 0.05 for at least one mask (that is, ignoring
those with evidence for association only under the SKAT model), we compared the
direction of effect estimated for the mask with lowest P-value mask to that estimated
for the same (or analogous) mask in the GHS or CHARGE analysis. We then conducted a one-sided exact binomial test to assess whether the fraction of results with
consistent direction of effects was significantly greater than expected by chance.
Gene set analysis in sequencing data. We curated 16 sets of candidate T2Drelevant genes, defined in Supplementary Table 9 with criteria as specified in
the Supplementary Methods. For each gene set, we constructed sets of matched
genes with similar numbers and frequencies of variants within them (details are
provided in the Supplementary Methods). A sensitivity analysis of this matching
strategy is presented in the Supplementary Methods.
To conduct a gene set analysis, we then combined the genes in the gene set with
the matched genes. Within the combined list of genes, we ranked genes using the
P values observed for the minimum P-value burden test. We then used a one-side
Wilcoxon rank-sum test to assess whether genes in the gene set had significantly
higher ranks than the comparison genes.

Use of gene-level associations to predict effector genes. To assess whether genelevel associations from exome sequencing—which are composed mostly of rare
variants independent of any GWAS associations—could prioritize potential effector
genes within known T2D GWAS loci, we first assessed whether predicted effector
genes (based on common-variant associations) were also enriched for rare coding
variant associations. Our analysis (described in full in the Supplementary Methods)
indicated that effector genes predicted from common coding variant associations
do show significant enrichments (P = 8.8 × 10−3), but effector genes predicted
from transcript-level associations do not (P = 0.72).
We then curated a list of 94 T2D GWAS loci, and 595 genes that were within
250 kb of any T2D GWAS index variant, from a 2016 T2D genetics review69 and
observed 40 with a P < 0.05 gene-level signal (Supplementary Table 12), greater
than the 595 × 0.05 = 29.75 expected by chance (P = 0.038). Only three (SLC30A8,
PAM and HNF1A) were from the list that we curated of 11 genes with causal
common coding variants6. We found that these 40 genes were significantly more
enriched for protein interactions (P = 0.03; observed mean = 11.4, expected
mean = 4.5) than the 184 genes implicated based on proximity to the index SNP
(P = 0.64; observed mean = 21.1, expected mean = 21.9), although evaluation of
the biological candidacy of these genes will ultimately require in-depth functional
studies70. Rare coding variants could therefore, in principle, complement common-variant fine-mapping71,72 and experimental data4,70 to help to interpret T2D
GWAS associations; however, our results indicate that much larger sample sizes
and/or orthogonal experimental data will be required to clearly implicate specific
effector genes. A full description of this analysis is included in the Supplementary
Methods.
Use of gene-level associations to predict direction of effect. To assess whether
gene-level association analyses of predicted deleterious variants could be used to
predict therapeutic direction of effect, we compared odds ratios estimated from
a modified weighted burden test procedure (described in the Supplementary
Methods) to those expected for T2D drug targets (assuming agonist targets to
have true odds ratios > 1 and inhibitors to have true odds ratios < 1). For a similar
comparison to expectations for mouse gene knockouts, we used the relationship
between mouse phenotype and human phenotype specified in the Supplementary
Methods. Genes present in two gene sets with opposite expected direction of effects
were excluded from this analysis.
Collection and analysis of SNP array data. To compare discoveries from our
exome-sequencing analyses to discoveries possible from common-variant GWAS
of the same samples, we aggregated all available SNP array data for the exomesequenced samples (18,233 cases and 17,679 controls; Supplementary Table 13).
After sample and variant quality control (described in the Supplementary
Methods), we imputed variants from the 1000 Genomes Phase 332 (1000G) and
Haplotype Reference Consortium33 (HRC) reference panels using the Michigan
Imputation Server73. We used 1000G-based imputation for all association analyses and HRC-based imputation to assess the number of exome-sequence variants
imputable from the largest available European reference panel (details available in
the Supplementary Methods).
After imputation, we performed sample and variant quality control, as well
as two-sided association tests, analogous to the exome-sequence single-variant
analyses. In contrast to the exome-sequencing analyses, a quantile–quantile plot
suggested that the associations from the EMMAX test were not well calibrated, and
we therefore used only the Firth test (that is, for both P values and odds ratios) in
the imputed GWAS analysis.
To conduct gene set analysis with the imputed GWAS data, we first used the
method implemented in MAGENTA74 to calculate gene scores from the imputed
GWAS single-variant association results. Following the same protocol as for gene
set analysis from the exome-sequencing results, we then conducted a one-sided
Wilcoxon rank-sum test to compare the gene scores to those of matched comparison genes. We followed the same approach for the gene set analysis that we
conducted in a larger, previously published13 GWAS.
LVE calculations. To calculate LVEs, we used a previously presented formula75
(equations are available in the Supplementary Methods) to calculate the LVE of a
variant with three genotypes (AA, Aa and aa) and corresponding relative risks (1,
RR1 and RR2). When presenting the strongest LVE values for the imputed GWAS
analysis, we only considered variants that were genotyped in at least 10,000 individuals to avoid potential artefacts that result from a spurious association in a
small-sample subgroup. For gene-level LVE calculations, we used the variant mask
with lowest P value to calculate LVEs. We also conducted a sensitivity analysis to
bound the extent to which our gene-level LVE estimates might be biased downwards due to their inclusion of benign alleles; this analysis (described in full in
the Supplementary Methods) produced upper bounds of gene-level LVEs that were
at most twofold higher than the point estimates.
Prediction of LVE explained by the top 100 and top 1,000 gene-level associations. To forecast the LVE that will be explained once 100 (or 1,000) significant T2D gene-level associations are detected, we applied a previously suggested
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model34 in which the LVE of a gene is related to its rank in the overall gene-level
P-value distribution. Specifically, the model is LVEn = ean + b where LVEn is the LVE
of the gene with nth lowest gene-level P value. We fitted this model using linear
regression to the top 50 genes in our analysis (Supplementary Fig. 20), yielding
estimates of a = −0.044 and b = −7.07. We then calculated the LVE of the top
100 (or 1,000) genes by summing the actual LVE of the top three signals (which
achieved exome-wide significance in our analysis) with the LVE predicted by the
model for genes ranked 4–100 (or 4–1,000).
Estimated power to detect gene-level associations with T2D drug targets. To
estimate the power of future studies to detect gene-level associations in genes with
effect sizes similar to those for established T2D drug targets, we used aggregate
allele frequencies and odds ratios estimated from our gene-level analysis and an
assumed prevalence of K = 0.08 to calculate a proxy for true population frequencies
and relative risks. For each gene, we used odds ratios and frequencies from the
variant mask that yielded the strongest gene-level association. Because, on average, these drug targets had five effective tests per mask, we used an exome-wide
significance threshold of α = 1.25 × 10−7 for power calculations. We calculated
power as previously described76.
The ranges given in the main text (75,000–185,000 disease cases) represent the
numbers from the power calculations for INSR (the drug target with the highest
observed effect size) and IGF1R (the drug target with the lowest observed effect
size other than KCNJ11 and ABCC8). We excluded KCNJ11 and ABCC8 from this
reported range, given that a mixture of risk-increasing and risk-decreasing variants
in these genes probably diluted their burden signals. We did not account for uncertainty in estimated odds ratios or aggregate variant frequency in these calculations,
as no genes had 95% confidence intervals that that did not overlap odds ratio = 1.
Interpretation of suggestive associations. We quantified the PPA for nonsynonymous variants observed in our dataset as a function of association strength measured by single-variant P values. We define a true association as a variant that, when
studied in larger sample sizes, will eventually achieve statistical significance owing
to a true odds ratio ≠ 1. We distinguish true associations from causal associations:
causally associated variants are the subset of truly associated variants in which the
variant itself is causal for the increase in disease risk, as opposed to being truly
associated due to linkage disequilibrium (LD) with a different causally associated
variant (that is, an ‘LD proxy’). An overview of the method that we developed for
PPA calculations is provided in Extended Data Fig. 7, and a full description of the
method is included in the Supplementary Methods. Here, we outline the steps in
the approach.
First, for various single-variant P-value thresholds in the exome-sequencing
analysis, we calculated the fraction of variants that reached this threshold with
directions of effect concordant with those of an independent exome array study10.
For example, 61.3% of nonsynonymous variants within T2D GWAS loci that
reached P < 0.05 in the exome-sequencing analysis had concordant directions
of effect with the independent study, a fraction that decreased (as expected) for
higher P-value thresholds (for example, 49.4% at P > 0.5) or when only variants
outside of T2D GWAS loci were analysed (51.9% at P < 0.05).
Second, we derived an equation to convert the fraction of concordant associations to an estimated proportion of true associations. This value provides a PPA
estimate, as a function of P value, for an arbitrary variant in the set initially used
to calculate direction of effect concordances. We computed separate mappings
for arbitrary nonsynonymous variants (using all exome-wide nonsynonymous
variants) and one for nonsynonymous variants within GWAS loci (using only nonsynonymous variants within the 94 T2D GWAS loci). We note that the mapping
produced from our analysis applies only to the results from the current study:
because other studies have different sample sizes and may apply different statistical
tests, the mapping would need to be recomputed to interpret the associations of
other studies using the same method.
Third, we converted PPA estimates to estimates of the posterior probability of
causal associations (PPAc). This conversion requires estimates of the fraction of
coding variant associations that are causal (as opposed to LD proxies). We explored
several values for this parameter, as described in the Supplementary Methods and
shown in Extended Data Fig. 8.
Fourth, we extended PPA estimates to incorporate gene-specific priors by
mapping posterior odds of causal association (POc) to a Bayes factor for causal
association (BFc). This calculation requires a set of training variants with a known
prior. For this training set, we use nonsynonymous variants within GWAS loci
and modelling assumptions for their prior. Details of this model are described in
the Supplementary Methods and a sensitivity analysis of its assumptions is shown
in Extended Data Fig. 8.
Finally, as a preliminary estimate of a principled prior likelihood for genes in
the mouse NIDD gene set, we estimated the proportion of non-null associations
across all genes in the set. To use true prior data (rather than associations from the
current study), we calculated gene-level P values for each gene in the set using the
MAGENTA74 algorithm applied to a recent transethnic T2D GWAS13. We then

used a previously developed approach40,77 that models the distribution of observed
P values as a mixture of uniform (representing the null distribution) and beta (representing the non-null distribution) distributions, yielding a prior value of 23.2%.
Our PPAc calculations currently have several limitations. They apply only to
single-variant associations and not (yet) to gene-level associations; extending them
to apply to gene-level associations would avoid the possibility of conflicting results
among variants within a gene but would require larger-scale gene-level replication
data than that we had available in the current analysis. Additional work will also be
needed to generate data and develop methods to estimate objective rather than subjective gene priors (researchers can often overestimate evidence of disease relevance
for genes in which they have invested considerable effort), to reduce dependence of
our conclusions on modelling assumptions (Extended Data Fig. 8) and to explore
the extent to which the large number of variant associations that we predict from
our data localize to specific gene or variant functional annotations78.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this paper.
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test, gene set enrichment analyses and the proportion of true associations as a
function of variant P values.
46. The SIGMA Type 2 Diabetes Consortium. Association of a low-frequency variant
in HNF1A with type 2 diabetes in a Latino population. J. Am. Med. Assoc. 311,
2305–2314 (2014).
47. Fu, W. et al. Analysis of 6,515 exomes reveals the recent origin of most human
protein-coding variants. Nature 493, 216–220 (2013).
48. Lohmueller, K. E. et al. Whole-exome sequencing of 2,000 Danish individuals
and the role of rare coding variants in type 2 diabetes. Am. J. Hum. Genet. 93,
1072–1086 (2013).
49. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122
(2016).
50. Liu, X., Wu, C., Li, C. & Boerwinkle, E. dbNSFP v3.0: a one-stop database of
functional predictions and annotations for human nonsynonymous and
splice-site SNVs. Hum. Mutat. 37, 235–241 (2016).
51. Jagadeesh, K. A. et al. M-CAP eliminates a majority of variants of uncertain
significance in clinical exomes at high sensitivity. Nat. Genet. 48, 1581–1586
(2016).
52. Kang, H. M. et al. Variance component model to account for sample structure in
genome-wide association studies. Nat. Genet. 42, 348–354 (2010).
53. Ma, C., Blackwell, T., Boehnke, M., Scott, L. J. & the GoT2D investigators.
Recommended joint and meta-analysis strategies for case–control association
testing of single low-count variants. Genet. Epidemiol. 37, 539–550 (2013).
54. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
55. The SIGMA Type 2 Diabetes Consortium. Sequence variants in SLC16A11 are a
common risk factor for type 2 diabetes in Mexico. Nature 506, 97–101 (2014).
56. Do, R. et al. Exome sequencing identifies rare LDLR and APOA5 alleles
conferring risk for myocardial infarction. Nature 518, 102–106 (2015).
57. Purcell, S. M. et al. A polygenic burden of rare disruptive mutations in
schizophrenia. Nature 506, 185–190 (2014).
58. Li, M. X., Gui, H. S., Kwan, J. S. & Sham, P. C. GATES: a rapid and powerful
gene-based association test using extended Simes procedure. Am. J. Hum.
Genet. 88, 283–293 (2011).
59. Mahajan, A. et al. Identification and functional characterization of G6PC2
coding variants influencing glycemic traits define an effector transcript at the
G6PC2-ABCB11 locus. PLoS Genet. 11, e1004876 (2015).
60. Chambers, J. C. et al. Common genetic variation near MC4R is associated with
waist circumference and insulin resistance. Nat. Genet. 40, 716–718 (2008).
61. The DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium.
Large-scale association analysis provides insights into the genetic architecture
and pathophysiology of type 2 diabetes. Nat. Genet. 44, 981–990 (2012).
62. Psaty, B. M. et al. Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium: design of prospective meta-analyses of
genome-wide association studies from 5 cohorts. Circ. Cardiovasc. Genet. 2,
73–80 (2009).
63. Yu, B. et al. Rare exome sequence variants in CLCN6 reduce blood pressure
levels and hypertension risk. Circ. Cardiovasc. Genet. 9, 64–70 (2016).
64. Brody, J. A. et al. Analysis commons, a team approach to discovery in a big-data
environment for genetic epidemiology. Nat. Genet. 49, 1560–1563 (2017).
65. Chen, H. et al. Control for population structure and relatedness for binary traits
in genetic association studies via logistic mixed models. Am. J. Hum. Genet. 98,
653–666 (2016).
66. Ramatenki, V. et al. Identification of new lead molecules against UBE2NL
enzyme for cancer therapy. Appl. Biochem. Biotechnol. 182, 1497–1517 (2017).
67. Gómez-Ramos, A., Podlesniy, P., Soriano, E. & Avila, J. Distinct X-chromosome
SNVs from some sporadic AD samples. Sci. Rep. 5, 18012 (2015).

RESEARCH Article
68. Jiang, Y. et al. Six novel rare non-synonymous mutations for migraine without
aura identified by exome sequencing. J. Neurogenet. 29, 188–194 (2015).
69. Flannick, J. & Florez, J. C. Type 2 diabetes: genetic data sharing to advance
complex disease research. Nat. Rev. Genet. 17, 535–549 (2016).
70. Thomsen, S. K. et al. Systematic functional characterization of candidate causal
genes for type 2 diabetes risk variants. Diabetes 65, 3805–3811 (2016).
71. Gaulton, K. J. et al. Genetic fine mapping and genomic annotation defines
causal mechanisms at type 2 diabetes susceptibility loci. Nat. Genet. 47,
1415–1425 (2015).
72. Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution
using high-density imputation and islet-specific epigenome maps. Nat. Genet.
50, 1505–1513 2018).
73. Das, S. et al. Next-generation genotype imputation service and methods. Nat.
Genet. 48, 1284–1287 (2016).
74. Segrè, A. V., Groop, L., Mootha, V. K., Daly, M. J. & Altshuler, D. Common inherited
variation in mitochondrial genes is not enriched for associations with type 2
diabetes or related glycemic traits. PLoS Genet. 6, e1001058 (2010).
75. So, H. C., Gui, A. H., Cherny, S. S. & Sham, P. C. Evaluating the heritability
explained by known susceptibility variants: a survey of ten complex diseases.
Genet. Epidemiol. 35, 310–317 (2011).
76. Skol, A. D., Scott, L. J., Abecasis, G. R. & Boehnke, M. Optimal designs for
two-stage genome-wide association studies. Genet. Epidemiol. 31, 776–788
(2007).
77. Pounds, S. & Morris, S. W. Estimating the occurrence of false positives and false
negatives in microarray studies by approximating and partitioning the
empirical distribution of P-values. Bioinformatics 19, 1236–1242 (2003).
78. Finucane, H. K. et al. Partitioning heritability by functional annotation using
genome-wide association summary statistics. Nat. Genet. 47, 1228–1235
(2015).
79. Scott, R. A. et al. An expanded genome-wide association study of type 2
diabetes in Europeans. Diabetes 66, 2888–2902 (2017).
80. Pickrell, J. K. Joint analysis of functional genomic data and genome-wide
association studies of 18 human traits. Am. J. Hum. Genet. 94, 559–573 (2014).
Acknowledgements Studies at the Broad Institute were funded as follows.
Sequencing for T2D-GENES cohorts was funded by the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) grant U01DK085526
(Multiethnic Study of Type Diabetes Genes) and National Human Genome
Research Institute (NHGRI) grant U54HG003067 (Large Scale Sequencing and
Analysis of Genomes). Sequencing for GoT2D cohorts was funded by National
Institutes of Health (NIH) 1RC2DK088389 (Low-Pass Sequencing and High
Density SNP Genotyping in Type 2 Diabetes). Sequencing for ProDiGY cohorts
was funded by NIDDK U01DK085526. Sequencing for SIGMA cohorts was
funded by the Carlos Slim Foundation (Slim Initiative in Genomic Medicine for
the Americas (SIGMA)). Analysis was supported by NIDDK grant U01DK105554
(AMP T2D-GENES Data Coordination Center and Web Portal). The Mount Sinai
IPM Biobank Program is supported by The Andrea and Charles Bronfman
Philanthropies. The Wake Forest study was supported by NIH R01 DK066358.
Oxford cohorts and analysis is funded by The European Commission (ENGAGE:
HEALTH-F4-2007-201413); MRC (G0601261, G0900747-91070); NIH
(RC2-DK088389, DK085545, R01-DK098032 and U01DK105535); Wellcome
Trust (064890, 083948, 085475, 086596, 090367, 090532, 092447, 095101,
095552, 098017, 098381, 100956, 101630 and 203141). The FUSION study
is supported by NIH grants DK062370 and DK072193. The research from the
Korean cohort was supported by a grant of the Korea Health Technology R&D
Project through the Korea Health Industry Development Institute (KHIDI),
funded by the Ministry of Health & Welfare, South Korea (grant numbers
HI14C0060, HI15C1595). The Malmö Preventive Project and the Scania
Diabetes Registry were supported by a Swedish Research Council grant (Linné)
to the Lund University Diabetes Centre. The Botnia and The PPP-Botnia studies
(L.G. and T.T.) have been financially supported by grants from Folkhälsan
Research Foundation, the Sigrid Juselius Foundation, The Academy of Finland
(grants 263401, 267882 and 312063 to L.G. and 312072 to T.T.), Nordic Center
of Excellence in Disease Genetics, EU (EXGENESIS, EUFP7-MOSAIC FP7600914), Ollqvist Foundation, Swedish Cultural Foundation in Finland, Finnish
Diabetes Research Foundation, Foundation for Life and Health in Finland, Signe
and Ane Gyllenberg Foundation, Finnish Medical Society, Paavo Nurmi
Foundation, Helsinki University Central Hospital Research Foundation, Perklén
Foundation, Närpes Health Care Foundation and Ahokas Foundation. The study
has also been supported by the Ministry of Education in Finland, Municipal
Heath Care Center and Hospital in Jakobstad and Health Care Centers in Vasa,
Närpes and Korsholm. The assistance of the Botnia Study Group is
acknowledged. This research was supported by contracts
HHSN268201200036C, HHSN268200800007C, HHSN268201800001C,
N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082,
N01HC85083 and N01HC85086, and grants U01HL080295 and
U01HL130114 from the National Heart, Lung and Blood Institute (NHLBI), with
additional contribution from the National Institute of Neurological Disorders
and Stroke (NINDS). Additional support was provided by R01AG023629 from
the National Institute on Aging (NIA). A full list of principal CHS investigators
and institutions can be found at CHS-NHLBI.org. The Jackson Heart Study (JHS)
is supported by contracts HHSN268201300046C, HHSN268201300047C,
HHSN268201300048C, HHSN268201300049C and HHSN268201300050C
from the NHLBI and the National Institute on Minority Health and Health
Disparities. J.G.W. is supported by U54GM115428 from the National Institute of
General Medical Sciences. The Diabetic Cohort (DC) and Multi-Ethnic Cohort
(MEC) were supported by individual research grants and clinician scientist

award schemes from the National Medical Research Council (NMRC) and the
Biomedical Research Council (BMRC) of Singapore. The DC, MEC, Singapore
Indian Eye Study (SINDI) and Singapore Prospective Study Program (SP2) were
supported by individual research grants and clinician scientist award schemes
from the NMRC and the BMRC of Singapore. The Longevity study at Albert
Einstein College of Medicine, USA was funded by The American Federation for
Aging Research, the Einstein Glenn Center and the NIA (PO1AG027734,
R01AG046949, 1R01AG042188 and P30AG038072). The TwinsUK study was
funded by the Wellcome Trust and European Community’s Seventh Framework
Programme (FP7/2007-2013) and received support from the National Institute
for Health Research (NIHR)-funded BioResource, Clinical Research Facility and
Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation
Trust in partnership with King’s College London. Framingham Heart Study is
supported by NIH contract NHLBI N01-HC-25195 and HHSN268201500001I.
This research was also supported by NIA AG08122 and AG033193, NIDDK
U01DK085526, U01DK078616 and K24 DK080140, NHLBI R01 HL105756,
and grant supplement R01 HL092577-06S1 for this research. We also
acknowledge the dedication of the FHS study participants without whom this
research would not be possible. The Mexico City Diabetes Study has been
supported by the following grants: RO1HL 24799 from the NHLBI; Consejo
Nacional de Ciencia y Tecnología 2092, M9303, F677-M9407, 251M, 2005C01-14502 and SALUD 2010-2151165; and Consejo Nacional de Ciencia y
Tecnología (CONACyT) (Fondo de Cooperación Internacional en Ciencia y
Tecnología (FONCICYT) C0012-2014-01-247974). The KARE cohort was
supported by grants from Korea Centers for Disease Control and Prevention
(4845–301, 4851–302, 4851–307) and an intramural grant from the Korea
National Institute of Health (2016-NI73001-00). The Diabetes in Mexico Study
was supported by Consejo Nacional de Ciencia y Tecnología grant number
S008-2014-1-233970 and by Instituto Carlos Slim de la Salud, AC. The
Atherosclerosis Risk in Communities study has been funded in whole or in part
with Federal funds from the NHLBI, NIH, Department of Health and Human
Services (contract numbers HHSN268201700001I, HHSN268201700002I,
HHSN268201700003I, HHSN268201700004I and HHSN268201700005I).
We thank the staff and participants of the ARIC study for their important
contributions. Funding support for ‘Building on GWAS for NHLBI-diseases: the
U.S. CHARGE consortium’ was provided by the NIH through the American
Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419). CHARGE
sequencing was carried out at the Baylor College of Medicine Human Genome
Sequencing Center (U54 HG003273 and R01HL086694). Funding for GO ESP
was provided by NHLBI grants RC2 HL-103010 (HeartGO) and exome
sequencing was performed through NHLBI grants RC2 HL-102925 (BroadGO)
and RC2 HL-102926 (SeattleGO). The infrastructure for the Analysis Commons
is supported by R01HL105756 (NHLBI, to B.M.P.), U01HL130114 (NHLBI, to
B.M.P.) and 5RC2HL102419 (NHLBI, to E. Boerwinkle). The LuCAMP project was
funded by the Lundbeck Foundation and produced by The Lundbeck
Foundation Centre for Applied Medical Genomics in Personalised Disease
Prediction, Prevention and Care (http://www.lucamp.org/). The Novo Nordisk
Foundation Center for Basic Metabolic Research is an independent Research
Center at the University of Copenhagen partially funded by an unrestricted
donation from the Novo Nordisk Foundation (https://cbmr.ku.dk/). Further
funding came from the Danish Council for Independent Research Medical
Sciences. The Inter99 was initiated by T. Jørgensen (principal investigator),
K. Borch-Johnsen (co-principal investigator), H. Ibsen and T. F. Thomsen. The
steering committee comprises the former two and C. Pisinger. The study was
financially supported by research grants from the Danish Research Council, the
Danish Centre for Health Technology Assessment, Novo Nordisk, the Research
Foundation of Copenhagen County, the Ministry of Internal Affairs and Health,
the Danish Heart Foundation, the Danish Pharmaceutical Association, the
Augustinus Foundation, the Ib Henriksen Foundation, the Becket Foundation
and the Danish Diabetes Association. D.R.W. is supported by the Danish
Diabetes Academy, which is funded by the Novo Nordisk Foundation. The KORA
study was initiated and financed by the Helmholtz Zentrum München—German
Research Center for Environmental Health, which is funded by the German
Federal Ministry of Education and Research (BMBF) and by the State of Bavaria.
Furthermore, KORA research was supported within the Munich Center of Health
Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ.
The NHLBI Exome Sequencing Project (ESP) was supported through the NHLBI
Grand Opportunity (GO) program and funded by grants RC2 HL103010
(HeartGO), RC2 HL102923 (LungGO) and RC2 HL102924 (WHISP) for
providing data and DNA samples for analysis. The exome sequencing for the
NHLBI ESP was supported by NHLBI grants RC2 HL102925 (BroadGO) and
RC2 HL102926 (SeattleGO). This research was supported by the Multi-Ethnic
Study of Atherosclerosis (MESA) contracts HHSN268201500003I,
N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162,
N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166,
N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040,
UL1-TR-001079 and UL1-TR-001420. The provision of genotyping data was
supported in part by the National Center for Advancing Translational Sciences,
TSCI grant UL1TR001881, and the National Institute of Diabetes and Digestive
and Kidney Disease Diabetes Research (DRC) grant DK063491. The San
Antonio Mexican American Family Studies (SAMAFS) are supported by the
following grants/institutes. The San Antonio Family Heart Study (SAFHS) and
San Antonio Family Diabetes/Gallbladder Study (SAFDGS) were supported by
U01DK085524, R01 HL0113323, P01 HL045222, R01 DK047482 and R01
DK053889. The Veterans Administration Genetic Epidemiology Study (VAGES)
study was supported by a Veterans Administration Epidemiologic grant. The
Family Investigation of Nephropathy and Diabetes - San Antonio (FIND-SA)

Article RESEARCH
study was supported by NIH grant U01DK57295. The SAMAFS research team
acknowledges the contributions of H. E. Abboud to the research activities of the
SAMAFS. Sample collection, research and analysis from the Hong Kong
Diabetes Register (HKDR) at the Chinese University of Hong Kong (CUHK) were
supported by the Hong Kong Foundation for Research and Development in
Diabetes established under the auspices of the Chinese University of Hong
Kong, the Hong Kong Government Research Grants Committee Central
Allocation Scheme (CUHK 1/04C), a Research Grants Council Earmarked
Research Grant (CUHK4724/07M), the Innovation and Technology Fund
(ITS/088/08 and ITS/487/09FP) and the Research Grants Committee Themebased Research Scheme (T12-402/13N). The TODAY contribution to this study
was completed with funding from NIDDK and the NIH Office of the Director (OD)
through grants U01DK61212, U01DK61230, U01DK61239, U01DK61242 and
U01DK61254; from the National Center for Research Resources General
Clinical Research Centers Program grants M01-RR00036 (Washington
University School of Medicine), M01-RR00043-45 (Children’s Hospital Los
Angeles), M01-RR00069 (University of Colorado Denver), M01-RR00084
(Children’s Hospital of Pittsburgh), M01-RR01066 (Massachusetts General
Hospital), M01-RR00125 (Yale University) and M01-RR14467 (University of
Oklahoma Health Sciences Center); and from the NCRR Clinical and
Translational Science Awards grants UL1-RR024134 (Children’s Hospital of
Philadelphia), UL1-RR024139 (Yale University), UL1-RR024153 (Children’s
Hospital of Pittsburgh), UL1-RR024989 (Case Western Reserve University),
UL1-RR024992 (Washington University in St Louis), UL1-RR025758
(Massachusetts General Hospital) and UL1-RR025780 (University of Colorado
Denver). The Pakistan Genetic Resource (PGR) is funded through endowments
awarded to CNCD, Pakistan. J.F. is supported by BADERC DK057521. R.L. is
supported by the NIH (R01DK110113, U01HG007417, R01DK101855 and
R01DK107786). A.P.M. is supported by the NIH-NIDDK (U01DK105535); and a
Wellcome Trust Senior Fellow in Basic Biomedical Science (award WT098017).
J.C.F. is supported by NIDDK K24 DK110550 and P30 DK057521. G.I.B. is
supported by P30 DK020595. Y.S.C. acknowledges support from the National
Research Foundation of Korea (NRF) grant (NRF-2017R1A2B4006508). C.-Y.C.
is supported by Clinician Scientist Award (NMRC/CSA-SI/0012/2017) of the
Singapore Ministry of Health’s National Medical Research Council. R.C.W.M. and
J.C. acknowledges support from the Hong Kong Research Grants Council
Theme-based Research Scheme (T12-402/13N), Research Grants Council
General Research Fund (14110415), the Focused Innovation Scheme, the ViceChancellor One-off Discretionary Fund, the Postdoctoral Fellowship Scheme of
the Chinese University of Hong Kong, as well as the Chinese University of Hong
Kong-Shanghai Jiao Tong University Joint Research Collaboration Fund. We
thank all medical and nursing staff of the Prince of Wales Hospital Diabetes
Mellitus Education Centre, Hong Kong. LuCAMP thanks A. Forman,
T. H. Lorentzen and G. J. Klavsen for laboratory assistance, P. Sandbeck for data
management, G. Lademann for secretarial support and T. F. Toldsted for grant
management. We thank study participants of the DC, MEC, SINDI and SP2 for
their contributions and the National University Hospital Tissue Repository
(NUHTR). We thank the Jackson Heart Study (JHS) participants and staff for
their contributions to this work. This study was provided with biospecimens and
data from the Korean Genome Analysis Project (4845-301), the Korean

Genome and Epidemiology Study (4851-302) and the Korea Biobank Project
(4851-307, KBP-2013-11 and KBP-2014-68) that were supported by the Korea
Centers for Disease Control and Prevention, South Korea. The Pakistan Genomic
Resource (PGR) thank all the study participants for their participation. For this
publication, biosamples from the KORA Biobank as part of the Joint Biobank
Munich (JBM) have been used. M.I.M. is a Wellcome Trust Senior Investigator
(WT098381) and a National Institute of Health Research (NIHR) Senior
Investigator; the views expressed in this article are his views and not necessarily
those of the NHS, the NIHR, or the Department of Health. The content is solely
the responsibility of the authors and does not necessarily represent the official
views of the National Institutes of Health.
Author contributions J.C.F., M.I.M. and M.B. contributed equally to this work. J.F.,
N.P.B., J.C.F., M.I.M. and M.B. provided leadership. J.F., J.M.M., C.F., M.S.U.,
A. Mahajan, J.W., T.M.T., T.W.B., L. Chen, S.C., A.E., A.U.J., K.M., A.N., A.J.P., N.W.R.,
N.R.R., H.M.S., J.M.T., R.P.W., L.J.S. and A.P.M. analysed data. L. Caulkins, R.K.
and M.C. provided project management and support. Members of the Broad
Genomics Platform Consortium contributed to the data generation for the
indicated studies. A.C., R.A.D., S.G., S.H., H.M.K., B.-J.K., H.A.K., J.K., J. Liu, K.L.M.,
M.C.Y.N., M.P., R.S.V., C.S., W.Y.S., C.H.T.T., F.T., B.T., R.M.v.D., M.V., T.-Y.W., G. Atzmon,
N.B., J.B., D.W.B., J.C.C., E. Chan, C.-Y.C., Y.S.C., F.S.C., R.D., B.G., J.S.K., S.H.K., M.L.,
D.M.L., E.S.T., J.T., J.G.W., E. Bottinger, J.C., J.D., P.F., M.Y.H., Y.J.K., J.-Y.L., J. Lee,
R.L., R.C.W.M., A.D.M., C.N.A.P., K.S.P., A.R., D.S., X. Sim, Y.Y.T., C.L.H., G. Abecasis,
G.I.B., N.J.C., M.S., R.S., J.B.M. and D.A. provided data and analysis from the
T2D-GENES study. V.L., L.L.B., L.G., P.N., T.D.S., T.T. and K.S.S. provided data and
analysis from the GoT2D study. M.E.J., A.L., D.R.W., N.G., T.H. and O.P. provided
data and analysis from the LuCAMP study. L.D., K.L.D., M.K., E.M.-D., C.P., N.S.,
B.B., P.Z. and D.D. provided data and analysis from the ProDiGY study. F.B.-O.,
F.C.-C., C.C.-C., E. Córdova, M.E.G.-S., H.G.-O., J.M.M.-H., A.M.-H., E.M.-C., C.R.-M.,
C. Gonzalez, M.E.G., C.A.A.-S., C.H., B.E.H., L.O., X. Soberón and T.T.-L. provided data
and analysis from the SIGMA study. J.W., E. Boerwinkle, J.A.B., J.S.F., N.L.H.-C.,
C.-T.L., A.K.M., A.C.M., B.M.P., S.W., P.S.d.V., J.D., S.R.H., C.J.O., J.P. and J.B.M.
provided data and analysis from the CHARGE study. T.M.T., J.B.L., A. Marcketta,
C.O., D.J.C., H.L.K., F.E.D., A.B. and D.J.C. provided data and analysis from the
Regeneron study. T.M.S., C. Gieger, T.M. and K.S. provided data and analysis from
the KORA study. E. Boerwinkle, M.G., N.L.H.-C., A.C.M., W.S.P., B.M.P., A.P.R., R.P.T.,
C.J.O., L.L., S.R. and J.I.R. provided data and analysis from the ESP study.
Competing interests P.Z. is a consultant for Merck, Daichii-Sankyo, BoerhingerIngelheim and Janssen; B.M.P. serves on the DSMB of a clinical trial funded
by Zoll LifeCor and on the Steering Committee of the Yale Open Data Access
Project funded by Johnson & Johnson.
Additional information
Supplementary information is available for this paper at https://doi.org/
10.1038/s41586-019-1231-2.
Peer review information Nature thanks Braxton Mitchell and the other
anonymous reviewer(s) for their contribution to the peer review of this work.
Reprints and permissions information is available at http://www.nature.com/
reprints.

RESEARCH Article

Extended Data Fig. 1 | Power analysis. The power to detect associations
(using a two-sided test) at P < 5 × 10−8 for variants (or collections of
variants) with a given minor allele frequency (x axis) and odds ratio
(y axis) measured as the average across all ancestries. a, Cells are shaded
according to the power of the current study of 20,791 T2D cases and
24,440 controls, with white indicating high power and red indicating low

power. The 20%, 50%, 80% and 99% contour lines are labelled. b, Cells are
shaded according to the difference in power between the current study and
a previously published study of 12,940 individuals10, with yellow–white
indicating a large increase in power and red indicating a small increase in
power. The 20%, 40%, 60% and 80% contour lines are labelled.
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Extended Data Fig. 2 | Data quality control workflow. A schematic of
the steps involved in sample and variant quality control is shown. Quality
control was conducted as described in the Methods to construct a set of
samples and variants included in the association analysis. Each step is
depicted as an arrow, with the number of samples or variants excluded
by the step shown at the end of the arrow. The final set of samples and
variants analysed are represented by the ‘Analysis’ dataset; we further
excluded samples of high relatedness to other samples in the dataset from
some but not all analyses. After each step that removed samples, we also
removed newly monomorphic variants (hence the decrease in variants
between the ‘Clean’ and ‘Analysis’ datasets).
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Extended Data Fig. 3 | See next page for caption.
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Extended Data Fig. 3 | Single-variant association analysis workflow.
A schematic of the steps involved in single-variant exome-sequencing
association analysis is shown, as described in the Methods. We began
analysis with a division of samples in the ‘Analysis’ dataset (leftmost
column) into 25 different subgroups (second column from the left) based
on cohort, ancestry and sequencing technology. We then filtered variants
according to metrics computed separately for each subgroup; we applied
the filters listed in the ‘Basic filters’ box to all subgroups and for some
subgroups we applied additional (more stringent) filters as indicated by
boxes in the third column from the left. The resulting number of variants
and samples advanced for analysis in each subgroup are indicated in
the fourth column from the left. We analysed each subgroup with both the
EMMAX test (to measure association strength) and the Firth test

(to measure allelic odds ratios), each of which are two-sided; the number
of principal components included as covariates in the Firth test is shown in
the fifth column from the left. Finally, we combined each of the EMMAX
and Firth subgroup-level results using a 25-group meta-analysis to
produce the final P values and odds ratios reported for each variant. Multi,
variant is multiallelic; CR, call rate; P, variant subgroup-level P value;
P(Fisher), variant subgroup-level P value from Fisher’s exact test; P(miss),
P value for subgroup-level variant differential missingness between
T2D cases and controls; P(HWE), P value for deviation from subgrouplevel Hardy–Weinberg equilibrium; Alt GQ, mean genotype quality of
non-reference genotypes (across all samples); X Chrom, variant is on
X chromosome.
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Extended Data Fig. 4 | Calibration of single-variant analysis. To assess
whether our single-variant association statistics (two-sided, calculated by
the EMMAX test) were well-calibrated, we computed quantile–quantile
plots of associations across all samples (Overall) and within each ancestry
(total n = 45,231 individuals). To avoid deflation of the quantile–quantile
plot from rare variants (for which the expected P values are discrete rather
than uniformly distributed), only variants with minor allele counts of
20 or greater (either overall or within the relevant ancestry) are shown.

Variants were also LD-pruned before plotting, to avoid induced variance
from correlated P values of these variants, using the ‘clump’ method
implemented in PLINK. The λ values indicate genomic control, as
measured by the ratio in observed median χ2 statistic to that expected
under the null hypothesis. Red line, expectation of P values under the
null distribution. Blue lines (and grey region), 95% confidence interval of
expectations under the null distribution.
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Extended Data Fig. 5 | Gene-level association analysis workflow.
A schematic of the steps involved in gene-level exome-sequencing
association analysis, as described in Methods, is shown. We began analysis
with subgroup-level genotype filtering (second column from the left) of
unrelated samples in the ‘Analysis’ dataset (leftmost column); we then
applied genotype filters for each subgroup (filtering genotypes for either
all or no samples in each subgroup), similar to those used in subgrouplevel single-variant analyses. We then annotated each non-reference
variant allele with 16 different bioinformatics algorithms to assess allele
deleteriousness, and we grouped alleles into one of seven nested masks
(third column from the left; the number of variants and weights shown
correspond to alleles absent from ‘higher’, or more stringent, nested masks).

We computed burden and SKAT analyses (both of which are two-sided)
using one of two approaches to combine alleles across masks (Methods):
first, by analysing all alleles at once with weights assigned according to the
most stringent mask containing the allele (weighted test); and second, by
analysing each mask independently and then calculating the lowest P value
corrected for the effective number of tests (minimum P-value test). Multi,
variant is multiallelic; CR, call rate; P(miss), P value for subgroup-level
variant differential missingness between T2D cases and controls; P(HWE),
P value for deviation from subgroup-level Hardy–Weinberg equilibrium;
Alt GQ, mean genotype quality of non-reference genotypes (across all
samples).
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Extended Data Fig. 6 | Calibration of gene-level association analyses.
For both the burden and SKAT tests, we tested for gene-level association
within seven different allelic masks. As this produced seven P values
for each test, we developed two means to consolidate these results
(Methods). a, b, The quantile–quantile plots of associations are shown for
the minimum P-value burden test (a) and the weighted burden test (b).
Each test is two-sided and consists of n = 43,071 unrelated individuals.
Only genes with combined minor allele count of 20 or greater are shown

in the quantile–quantile plots, to avoid deflation from genes with too
few variants to produce P values asymptotically uniform under the null
distribution. The λ values indicate genomic control, as measured by
the ratio in observed median χ2 statistic to that expected under the null
hypothesis. The three genes with exome-wide significant associations are
labelled. Red line, expectation of P values under the null distribution. Blue
lines (and grey region), 95% confidence interval of expectations under the
null distribution.
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Extended Data Fig. 7 | PPA calculation workflow. a, We estimated
the PPAs for nonsynonymous variants in our sequence analysis based
on concordance with independent exome array data and previously
published6,78,80 estimates of the fraction of causal coding associations
(Methods). b, PPA estimates for nonsynonymous variants within T2D
GWAS loci are shown as a function of P value (right y axis, black line;
95% confidence interval, grey shading) together with the total number of
such variants (left y axis, red line). c, For variants outside of T2D GWAS
loci, we developed a method to further compute Bayes factors, which
measure the odds of true and causal association, as a function of P value,

using a model of the prior odds of true and causal association for variants
in GWAS loci (Methods). d, These Bayes factors can be combined with a
subjective prior belief in the T2D relevance of a gene (y axis) to produce
the estimated posterior probability of true and causal association for
any nonsynonymous variant in the exome-sequence dataset based on its
observed log10(P) (x axis). Posterior estimates are shaded proportional to
value (red, low; white, high). Values are shown for the default modelling
assumptions of 33% of missense variants that caused gene inactivation and
30% of true missense associations that represented the causal variant.

RESEARCH Article

Extended Data Fig. 8 | Estimated posterior probability of associations
for different prior hypotheses. We estimated the posterior probability of
association for nonsynonymous variants that met various single-variant
P-value thresholds (two-sided EMMAX test, n = 45,231 individuals) in
our analysis, as described in the Methods and shown in Extended Data
Fig. 7. To perform the needed calculations, we assumed that, on average,
1.1 genes that are found within each T2D GWAS locus are relevant to T2D
and 33% of missense mutations within these genes cause gene loss-of-

function. a–f, To assess the sensitivity of our analysis to these assumptions,
we repeated the calculations with different assumptions of 0.5 (a), 2.0 (b),
0.25 (c) and 0.1 (d) T2D-relevant genes within each GWAS locus, as well
as 25% (e) and 40% (f) of missense variants leading to loss-of-function.
All analyses assume the default modelling parameters that 30% of true
nonsynonymous associations are causal associations; different values for
this parameter would scale posterior probability estimates linearly.
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Extended Data Table 1 | Most significant single-variant associations from exome-sequencing analysis

The most significant results from exome-sequencing single-variant association analyses are shown (n = 45,231 individuals). Gene, the closest gene to the variant. Variant, a unique identifier for the
variant within our exome-sequencing analysis. Consequence, the predicted consequence of the variant, defined by sequence ontology annotation and produced using VEP. Impact, the effect of the
variant, as predicted using VEP (Med, medium; Mod, modifier). Change, the predicted protein change, defined according to the ‘best guess’ transcript as described in the Methods. MAFs are calculated
as the maximum across all ancestries. Case, the number of samples with T2D carrying the variant. Ctrl, the number of samples without T2D carrying the variant. OR, the odds ratio, calculated from
the Firth analysis. P, the P value, calculated from the (two-sided) EMMAX analysis. Ref P: the P value of the variant in one of three previous GWAS or exome array analyses, referenced in the Ref
column6,13,79.
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Extended Data Table 2 | Most significant gene-level associations from exome-sequencing analysis

The most significant results from gene-level analyses are shown (n = 43,071 unrelated individuals). Genes are ranked according the (two-sided) minimum P value achieved across the four
gene-level analyses. Gene, a unique identifier for the gene within our exome-sequencing analysis. Var (CAF), the number of alleles (combined allele frequency (CAF) of variants) in the mask achieving
the strongest association across the four tests (that is, the 0/5 1% mask for the weighted test, or the mask with the minimum P value for the minimum P-value test). Burden, results from the
(two-sided) burden analysis. SKAT, results from the (two-sided) SKAT analysis. Min P, results from the (two-sided) minimum P-value analysis. Weighted, results from the (two-sided) weighted analysis.
OR, the odds ratio as estimated from the burden analysis. P, the (two-sided) P value for the indicated analyses.
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n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.

A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient)
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code
Data collection

No software was used in data collection

Data analysis

All software used in the analysis was open source and is described in the Methods section of the manuscript. Existing software packages
used were: RTA v2.7.3, BWA v0.7 , Picard v1, GATK v3.4, VEP v87, Plink 1.9, EPACTS v3.2.4, MetaXcan v0.3, DAPPLE, MAGENTA v2.4, R
v3.4, Michigan Imputation Server. Custom scripts (available for download as a zip file) were written to conduct the minimum p-value test,
perform the Wilcoxon rank sum test for gene sets, and estimate the fraction of true associations as a function of variant p-value.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers.
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

Sequence data and phenotypes for this study are available via the database of Genotypes and Phenotypes (dbGAP) and/or the European Genome-phenome
Archive, as indicated in Supplementary Table 1.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size

We conducted a power analysis (described in the text) to demonstrate that the 45,231 samples analyzed in the study provided a significant
increase in power to detect rare variant associations compared to previous studies. Power calculations were performed for frequency and
effect size combinations in the range of those previously hypothesized to exist for complex diseases like T2D.

Data exclusions

At the time of sample selection for sequencing, samples were excluded if they matched predetermined criteria for T1D or MODY as described
in Supplementary Table 1. At the analysis stage, excluded data were of three types. (a) Samples and (b) variants were excluded if they failed
quality control analyses (described in Methods). (c) ~3600 cases from the PRODiGY study were excluded because they did not have suitably
matched controls, resulting in inflated tests statistics as described in the Methods section. Exclusion criteria during the analysis stage were
determined based on inspection of the distribution of data.

Replication

We replicated our significant associations in independent datasets from CHARGE and GHS, as described in the main text. All three exome-wide
significant associations were replicated.

Randomization

Samples were allocated according to the cohort in which they were collected. Further control for confounding factors (imprecise ancestry
matching even within cohort, technical confounders) were controlled for by including covariates in the regression model used for association
analysis

Blinding

As our analysis involved a regression of phenotype on genotype, neither of which can be influenced by the analyst or data collector, blinding
was not relevant to our study
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Materials & experimental systems

Methods

n/a Involved in the study

n/a Involved in the study

Antibodies

ChIP-seq

Eukaryotic cell lines

Flow cytometry

Palaeontology

MRI-based neuroimaging

Animals and other organisms
Human research participants
Clinical data

Human research participants
Policy information about studies involving human research participants
Population characteristics are described in Supplementary Table 1. Relevant characteristics include age, sex, and BMI. For most
cohorts, patients with T2D had higher BMI and age, except for cohorts from the GoT2D study where lean, young cases and old,
obese controls were preferentially selected. Gender distribution varied by cohort.

Recruitment

Patients were recruited originally as a part of numerous cohort studies, described in Supplementary Table 1, each of which had
different selection criteria. For most cohorts, patients were recruited over a long period of time and then cases and controls
were selected for sequencing based on DNA and phenotyping quality. T2D diagnosis was determined by clinical data and not the
participants themselves. Some bias may have occurred in terms of patient response to recruitment but these are unlikely to be
correlated with genotype or have a significant effect on our analysis.

Ethics oversight

All samples were approved for use by their home institution’s institutional review board or ethics committee, as previously
reported (see references in the Methods section of the manuscript). Samples newly sequenced at The Broad Institute as part of
T2D-GENES, SIGMA, and ProDiGY are covered under Partners Human Research Committee protocol # 2017P000445/PHS
“Diabetes Genetics and Related Traits”.

October 2018

Population characteristics

2

Note that full information on the approval of the study protocol must also be provided in the manuscript.

nature research | reporting summary
October 2018

3

